Business ❯Market Competition

Pharmaceutical Industry

Weight Loss Drugs Eli Lilly Novo Nordisk Drug Development Drug Competition Vaccine Manufacturers Competitor Analysis Drug Formulary Market Dynamics Generic Drugs Rivalry Obesity Drug Market Eli Lilly vs Novo Nordisk Obesity Drugs

Novo Nordisk’s CagriSema Delivers 20.4% Weight Loss, Shares Drop

Investors have expressed skepticism over side effects alongside concerns about its delayed market debut following full trial results.

Novo Nordisk CEO Steps Down Following Share Price Collapse

Eli Lilly Reports Record Q1 Revenue but Faces Profit Pressure and Competitive Challenges

Pfizer Halts Development of Danuglipron After Liver Safety Concerns

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Novavax Reports Narrower Q4 Loss and Strategic Shift Away from COVID-19 Vaccine Commercialization

Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

Novo Nordisk's Amycretin Shows Promise as Next-Gen Weight Loss Drug